For Cincinnati patients who struggle with taking HIV meds every day, a monthly shot is looking like a seriously attractive alternative.
University of Cincinnati clinicians helped run a national trial that found long-acting injectable HIV therapy kept people on treatment more reliably than daily pills. The phase 3 LATITUDE trial reported substantially lower rates of "regimen failure" among participants who switched to monthly injections of cabotegravir plus rilpivirine compared with those who stayed on standard daily oral antiretroviral therapy. Full results landed this month in the New England Journal of Medicine.
Study Details And Numbers
According to the New England Journal of Medicine, LATITUDE enrolled 453 people in an initial phase focused on achieving viral suppression. Of those, 306 participants who got their virus under control were moved into Step 2 of the study: 152 were switched to monthly long-acting injections and 154 continued taking standard oral ART.
By week 48, the cumulative incidence of regimen failure was 22.8% in the injectable group compared with 41.2% in the oral-therapy group (difference 6.4 percentage points; P = 0.002). The gap was strong enough that the trial stopped randomizing people early in Step 2.
What Cincinnati Researchers Say
"This is a paradigm-shifting study," said Carl Fichtenbaum, MD, an author on the paper and an endowed professor at the University of Cincinnati. He noted that an intermittent, clinic-administered approach removes the daily reminder of pills and can help blunt stigma that still clings to HIV.
The University of Cincinnati reports it was the leading U.S. enrolling site, contributing 32 of the trial's 453 participants.
Why The Trial Was Stopped Early
Industry and trial organizers say an independent data-safety monitoring board recommended halting randomization after interim analyses showed a clear benefit from the injections. At that point, eligible participants were offered the long-acting regimen, according to ViiV Healthcare.
The sponsor and the ACTG framed the outcome as evidence that a long-acting option can reach people whose lives or circumstances make daily pills a poor fit.
Safety And Resistance Questions
The overall rate of adverse events was similar between the two groups, but investigators did see resistance-associated mutations in a small number of participants in each arm. That detail will need careful monitoring and follow-up, the authors cautioned in the New England Journal of Medicine.
Clinicians and advocates say the real test will be outside the controlled setting of a trial. Access to clinics, reliable follow-up for missed injections and local clinic capacity will all influence whether this strategy works in everyday practice.
Access And What Comes Next
Cabotegravir plus rilpivirine, sold as Cabenuva, is already approved as a long-acting complete regimen for certain patients. Researchers say LATITUDE's results could widen the group of people who might benefit from the shots, but they stress that real-world rollout will not be simple, according to ViiV Healthcare.
The study was funded in part by the NIH and conducted by the ACTG. Investigators say they will be watching longer-term follow-up and real-world implementation data to understand how durable the benefits are and how well clinics can make this option work for patients who need it most.
